2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on High-Risk HER2+ Early BC: Adjuvant T-DM1 + Pertuzumab vs. SoC - Did KAITLIN Study Demonstrate Improvement in IDFS?
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Kevin Kalinsky
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Kevin Kalinsky
Comments 0
Login to view comments.
Click here to Login
